- Home
- AIRT vs MNOV Comparison
AIRT vs MNOV Comparison
Compare AIRT & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRT
- MNOV
- Stock Information
- Founded
- AIRT 1980
- MNOV 2000
- Country
- AIRT United States
- MNOV United States
- Employees
- AIRT N/A
- MNOV N/A
- Industry
- AIRT Air Freight/Delivery Services
- MNOV Biotechnology: Pharmaceutical Preparations
- Sector
- AIRT Consumer Discretionary
- MNOV Health Care
- Exchange
- AIRT Nasdaq
- MNOV Nasdaq
- Market Cap
- AIRT 59.0M
- MNOV 68.2M
- IPO Year
- AIRT N/A
- MNOV 2005
- Fundamental
- Price
- AIRT $21.40
- MNOV $1.29
- Analyst Decision
- AIRT
- MNOV Strong Buy
- Analyst Count
- AIRT 0
- MNOV 2
- Target Price
- AIRT N/A
- MNOV $7.00
- AVG Volume (30 Days)
- AIRT 3.9K
- MNOV 50.4K
- Earning Date
- AIRT 08-22-2025
- MNOV 08-26-2025
- Dividend Yield
- AIRT N/A
- MNOV N/A
- EPS Growth
- AIRT N/A
- MNOV N/A
- EPS
- AIRT N/A
- MNOV N/A
- Revenue
- AIRT $291,850,000.00
- MNOV N/A
- Revenue This Year
- AIRT N/A
- MNOV N/A
- Revenue Next Year
- AIRT N/A
- MNOV N/A
- P/E Ratio
- AIRT N/A
- MNOV N/A
- Revenue Growth
- AIRT 1.75
- MNOV N/A
- 52 Week Low
- AIRT $14.56
- MNOV $1.12
- 52 Week High
- AIRT $26.70
- MNOV $2.55
- Technical
- Relative Strength Index (RSI)
- AIRT 46.80
- MNOV 43.00
- Support Level
- AIRT $21.07
- MNOV $1.26
- Resistance Level
- AIRT $22.01
- MNOV $1.40
- Average True Range (ATR)
- AIRT 0.81
- MNOV 0.07
- MACD
- AIRT -0.27
- MNOV -0.01
- Stochastic Oscillator
- AIRT 8.85
- MNOV 1.83
About AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.